Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
HUMA · NASDAQ · Biological Products, (No Diagnostic Substances)
Humacyte (HUMA) · oqro.io/stocks/HUMA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.5584−0.037 (−6.21%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
Including 17 routine filings (option exercises, tax withholding, grants, gifts). Open-market trades only
Insider filing
Traded Oct 6 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Oct 6 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
8 days before an 8-KTraded Sep 14 · filed 1 day later
Since the trade −0.5% · S&P 500 −0.9% · to Nov 13
A Humacyte director paid $5.6K out of pocket for Humacyte shares. Shares held went up 25% with this purchase.
Traded Aug 17 – Aug 20, 2026 · largest single transaction ~$18K
Aug 20, 2026~$6.9K · 10K sh @ $0.693
DetailsOfficial recordInsider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Jun 11 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider buying
Bought outside the usual windowTraded May 19 · filed 1 day later
Since the trade −32.3% · S&P 500 +2.8% · to Nov 13
A Humacyte director paid $50K out of pocket for Humacyte shares. 1 other person at Humacyte bought some too, in the same month. Shares held went up 62% with this purchase.
Insider buying
Bought outside the usual windowTraded May 18 · filed 2 days later
Since the trade −37.9% · S&P 500 +2.1% · to Nov 13
A Humacyte director paid $9.8K out of pocket for Humacyte shares. 1 other person at Humacyte bought some too, in the same month. Shares held went up 33% with this purchase.
Dale A. Sander (CFO and Chief Corp. Dev. Off) sold ~$41K of Humacyte
Planned saleShamik J Parikh (Chief Medical Officer) sold ~$41K of Humacyte
Planned saleInsider filing
Traded Nov 16, 2025 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 16, 2025 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 16, 2025 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Insider filing
Traded Nov 16, 2025 · filed 1 day later
Compensation award — excluded from discretionary-purchase analysis.
Traded Aug 18 – Aug 20, 2025 · largest single transaction ~$1.79MNot reported under a pre-arranged trading plan
Aug 19, 2025~$1.79M · 1.1M sh @ $1.63
DetailsTraded Aug 18 – Aug 20, 2025 · largest single transaction ~$1.79MNot reported under a pre-arranged trading plan
Aug 19, 2025~$1.79M · 1.1M sh @ $1.63
DetailsInsider buying
Traded Apr 14, 2025 · filed 1 day later
Since the trade −62.5% · S&P 500 +39.9% · to Nov 13
Humacyte's Chief Commercial Officer paid $10K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 42% with this purchase.
Insider buying
Traded Apr 10, 2025 · filed 4 days later
Since the trade −64.4% · S&P 500 +43.8% · to Nov 13
The CFO of Humacyte paid $31K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 97% with this purchase.
Insider buying
Traded Apr 10, 2025 · filed 4 days later
Since the trade −64.4% · S&P 500 +43.8% · to Nov 13
Humacyte's Chief Medical Officer paid $12K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month.
Insider buying
Traded Apr 8, 2025 · filed the same day
Since the trade −51.4% · S&P 500 +51.9% · to Nov 13
A Humacyte director paid $66K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 121% with this purchase.
Insider buying
Traded Apr 7, 2025 · filed 1 day later
Since the trade −55.7% · S&P 500 +49.6% · to Nov 13
A Humacyte director paid $20K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 94% with this purchase.
Insider buying
Traded Apr 8, 2025 · filed the same day
Since the trade −51.4% · S&P 500 +51.9% · to Nov 13
A Humacyte director paid $7.7K out of pocket for Humacyte shares. 5 other people at Humacyte bought some too, in the same month. Shares held went up 250% with this purchase.
Insider buying
Traded Dec 4, 2024 · filed the same day
Since the trade −87.4% · S&P 500 +24.1% · to Nov 13
A Humacyte director paid $20K out of pocket for Humacyte shares. 2 other people at Humacyte bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 19, 2024 · filed 2 days later
Since the trade −87.4% · S&P 500 +27.8% · to Nov 13
The CEO of Humacyte paid $8K out of pocket for Humacyte shares. 2 other people at Humacyte bought some too, in the same month. It was the first purchase in over a year.
Insider buying
Traded Nov 19, 2024 · filed 2 days later
Since the trade −87.4% · S&P 500 +27.8% · to Nov 13
A Humacyte director paid $8K out of pocket for Humacyte shares. 2 other people at Humacyte bought some too, in the same month. It was the first purchase in over a year.
Insider selling
Traded Nov 18, 2024 · filed 3 days laterNot reported under a pre-arranged trading plan
Since the trade −87.4% · S&P 500 +28.3% · to Nov 13
The CEO of Humacyte sold $3.6M of Humacyte shares. The filing does not indicate a pre-arranged trading plan.
Aug 17, 2026~$18K · 30K sh @ $0.594
DetailsOfficial recordAug 18, 2025~$1.01M · 549K sh @ $1.83
DetailsOfficial recordAug 20, 2025~$935K · 592K sh @ $1.58
DetailsOfficial recordAug 18, 2025~$1.01M · 549K sh @ $1.83
DetailsOfficial recordAug 20, 2025~$935K · 592K sh @ $1.58
DetailsOfficial record5 open-market purchases and 2 open-market sales by insiders of HUMA between Oct 13, 2025 and today, placed against the company's last 4 earnings releases. The latest on file was filed Nov 10, 2026.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Nov 10, 2026 | None | None | None |
| Aug 12, 2026 | None | None | 2 purchases |
| Mar 19, 2026 | None | None | None |
| Nov 12, 2025 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies